Page 1

NOVACYT GROUP Novacyt S.A. ( " Novacyt " , the " Company " or the " Group " ) Half year 2021 results Solid underlying financial performance and well - positioned for continued growth - 27 September 2021 - Paris , France and Camberley , UK Novacyt ( EURONEXT GROWTH : ALNOV ; AIM : NCYT ) , an international specialist in clinical diagnostics , announces its unaudited results for the half year ended 30 June 2021 . Graham Mullis , Group CEO of Novacyt , commented : " During 2021 , Novacyt has remained at the forefront in its response to the constantly changing global COVID - 19 pandemic . We have launched 18 new COVID - 19 products since the beginning of 2021 and we expect Novacyt to continue to play a major role in COVID- 19 testing well into 2022. We also remain focused on strengthening our long - term position and executing against our strategy by building our product and instrument platforms and expanding our commercial infrastructure for growth beyond COVID - 19 . " As my last results as CEO of Novacyt , I would like to take this opportunity to say it has been a privilege and an honour to lead the Company and to work alongside so many talented people who have worked tirelessly in the face of the unprecedented pandemic . I believe Novacyt is better positioned today than it has ever been , based on the capabilities it has developed over the last few years . I am immensely proud of what we have achieved , and I am confident the Company will continue to grow and cement its place as a leading global diagnostics player . " Financial highlights · • • • Group consolidated unaudited revenue of £ 54.0m ( H1 2020 : £ 63.3m ) excluding £ 40.8m of H1 DHSC revenues whilst the contract dispute continues Non - DHSC revenue increased by 20 % to £ 54.0m ( H1 2020 : £ 44.8m ) supported by growing UK private testing market The Group has booked exceptional cost of sales of £ 35.8m in connection with the DHSC contract dispute to write down inventory and terminate supply agreements that the Company had built in anticipation of further DHSC demand and to book the cost of products supplied to the DHSC in 2021 that have not been paid for Group gross margin before exceptional items was 71 % , delivering a gross profit of £ 38.0m . After the exceptional DHSC related cost of sales , gross margin drops to 4 % , delivering a gross profit of £ 2.3m Group adjusted EBITDA of £ 23.2m before exceptionals ( H1 2020 : £ 43.1m ) Operating loss of £ 13.6m compared to a profit of £ 42.2m in H1 2020 , driven by the one - time exceptional cost of sales and stock write - down Loss after tax of £ 12.7m compared to a profit of £ 35.1m in H1 2020 . Cash at 30 June 2021 of £ 77.2m with zero debt